Quick Facts

• Cattle: Helps reduce clinical signs in acute respiratory infection (with antibiotics). Supports management of clinical signs associated with diarrhea (with re-hydration therapy). Used as adjunctive care for acute mastitis (with antibiotics). Offers relief of post-operative discomfort after dehorning.
• Pigs: Supports the reduction of symptoms related to non-infectious lameness and inflammation in locomotor disorders. Used as adjunctive care for puerperal septicaemia and toxaemia (with antibiotics).
• Horses: Used for the alleviation of inflammation and support in the management of pain associated with acute and chronic musculo-skeletal disorders. Provides support for pain associated with equine colic.

---

Animeloxan is a veterinary medicinal product that may be used to support the management of various conditions in cattle, pigs, and horses. The product's intended uses relate to addressing inflammation and associated pain across different body systems.

For cattle, it is used as part of a therapeutic regimen to reduce clinical signs during acute respiratory infection and to help manage discomfort linked to diarrhea in calves over one week of age, both when combined with appropriate supporting therapies. It also functions as an element of adjunctive therapy for acute mastitis. Furthermore, it supports the relief of post-operative discomfort following dehorning in calves.

In pigs, Animeloxan supports the reduction of inflammation and symptoms of lameness associated with non-infectious locomotor disorders. It is also administered as adjunctive care, alongside antibiotic therapy, for conditions like puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome).

For horses, this product is used to help with the alleviation of inflammation and to offer support in relieving pain related to both acute and chronic musculo-skeletal issues. It may also provide relief of discomfort associated with equine colic, though professional re-evaluation is necessary if pain relief is inadequate.

Regulatory References

1. HPRA Veterinary Medicinal Product Overview

Who Can and Cannot Use Animeloxan?

The population eligibility for Animeloxan (veterinary Meloxicam) is strictly defined by regulatory contraindications and age-specific limitations, prohibiting use in certain animal populations. Eligibility is granted only to the approved target species (Cattle, Pigs, Horses, Dogs, and Cats) based on the specific formulation and indication.

---

Absolute Contraindications

Animeloxan must not be used in animals exhibiting:

• Impaired organ function: Severe hepatic, cardiac, or renal impairment.
• Bleeding risks: Haemorrhagic disorders or evidence of gastrointestinal ulceration or bleeding.
• Hypersensitivity: Known reactions to the active substance or excipients.

---

Age and Physiological Restrictions

Regulatory labeling establishes minimum age restrictions. The medicine is contraindicated in dogs and cats less than six weeks of age, in horses less than six weeks of age, and in calves less than one week of age for certain uses. Furthermore, concurrent use with other NSAIDs or glucocorticosteroids is prohibited.

Use is highly restricted in animals that are dehydrated, hypovolaemic, or hypotensive, as regulatory documents state that use must be avoided in these physiological states due to risk of renal toxicity.

---

Pregnancy and Lactation

Use is contraindicated for mares (horses) during pregnancy and lactation. Conversely, use is permitted in cows and sows (cattle and pigs) during these periods, subject to mandatory withdrawal periods.

Animeloxan's official interaction profile, based on regulatory documentation, defines specific restrictions concerning co-administration with other medicinal products. The documented interactions are primarily centered on the risk of additive adverse effects (pharmacodynamic) and pharmacokinetic competition.

---

Prohibited Co-administration and High-Risk Combinations

Animeloxan must not be administered concurrently with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or Glucocorticosteroids. This prohibition is documented due to the potential for significant additional or increased adverse effects. The use of Animeloxan with Diuretics, Anticoagulants, and Aminoglycoside Antibiotics carries a documented risk of toxic effects due to combined effects on renal function or coagulation. Furthermore, administration should be avoided in animals that are dehydrated, hypovolaemic, or hypotensive, as this physiological state is officially noted to increase the potential risk of renal toxicity. These restrictions are based on formal statements in the product labeling.

---

Administration Rules and Pharmacokinetic Notes

The regulatory labeling includes mandatory timing rules for treatment initiation. A treatment-free period of at least 24 hours must be observed when switching to Animeloxan from a prior anti-inflammatory product. In terms of drug competition, certain highly plasma protein-bound substances may interact with Animeloxan by competing for binding sites. This pharmacokinetic interaction could potentially lead to toxic effects due to elevated plasma concentrations of the free drug. Additionally, the oral suspension formulation is to be administered with food as a procedural interaction constraint.

The following text describes the pharmacodynamic mechanism of Animeloxan (Meloxicam), strictly adhering to all constraints.

How Animeloxan Works

Animeloxan exerts its action by preferentially targeting and modulating key enzyme systems across multiple physiological pathways. The core mechanism involves the non-covalent inhibition of the Cyclooxygenase-2 (COX-2) enzyme, which is responsible for generating prostanoid mediators. This interaction modifies the early molecular steps in the prostaglandin synthesis cascade, specifically leading to a marked reduction in the production of Prostaglandin E2 (PGE₂).

By suppressing PGE₂ levels, the mechanism initiates a cascade that influences both peripheral and central pathways. In peripheral tissues, reduced PGE₂ prevents the sensitization of nociceptors (pain receptors), leading to a decreased sensitization of peripheral nociceptors. Centrally, the inhibition of PGE₂ production in the hypothalamus contributes to the lowering of the hypothalamic thermoregulatory set-point.

The selectivity of the mechanism is subject to concentration-dependence: while preferential for COX-2, its influence increases over the constitutive COX-1 enzyme at higher concentrations. The mechanism remains specific to eicosanoid pathways and does not affect inflammatory responses driven by non-prostanoid mediators, such as leukotrienes.

Animeloxan, provided as a 20 mg/ml solution for injection, is administered according to regimens defined by species-specific routes and weight-based calculations. The product is intended primarily for parenteral use (injection). The standard dosage regimens differ by animal species and are based on a milligram-per-kilogram calculation to ensure the correct volume is delivered.

Species	Approved Route of Administration	Labeled Dosing Regimen
Cattle	Subcutaneous or Intravenous	0.5 mg meloxicam per kg body weight
Pigs	Intramuscular	0.4 mg meloxicam per kg body weight
Horses	Intravenous	0.6 mg meloxicam per kg body weight

For horses and cattle, the usage protocol is generally restricted to a single administration only, serving as an acute, short-term measure. In contrast, the initial intramuscular dose in pigs, which is administered in the anterior neck region, may be repeated once after a 24-hour interval; it is recommended to alternate injection sites if a second administration is required. Furthermore, for certain infectious conditions in cattle and pigs, administration is categorized as adjunctive treatment and must be used alongside appropriate concurrent therapies, such as antibiotics or oral re-hydration. Accurate body weight determination is required before administration in all cases to ensure compliance with the species-specific dose rate and proper procedural use.

Research evidence / Overview of studies for Animeloxan

Animeloxan (Meloxicam) is a veterinary medicine whose active ingredient has been the subject of research exploring pain and inflammation patterns across several animal species. The evidence landscape primarily consists of clinical trials and supporting bioequivalence studies which are applied in research contexts to authorize the generic product based on the established therapeutic profile of the original compound.

---

Research Evidence for Animeloxan in Cattle

This section was studied for various conditions. The research was evaluated in combination with other supportive care outlined in study protocols.

Studies for Acute Febrile Respiratory Disease and Mastitis

Research was evaluated in cattle presenting with conditions involving periods of heightened symptoms, specifically acute febrile respiratory disease and acute mastitis. These studies were conducted during periods of increased symptom activity and used short-term Randomized Controlled Trials (RCTs). The outcomes measured included tracking changes in clinical signs, such as rectal temperature and respiratory function scores, alongside overall measures of clinical status.

Studies for Pain Management and Inflammation

Research examined its use during the immediate post-operative period following dehorning in calves, focusing on outcomes related to physical discomfort. The research describes observations of the active substance in calves with diarrhea, where the protocol mandated concurrent oral re-hydration therapy.

---

Research Evidence for Animeloxan in Horses

Research examined the product's applicability in conditions marked by functional limitations, specifically musculo-skeletal disorders and conditions associated with acute or disruptive episodes like equine colic. Research was conducted on its use in horses presenting with signs of both acute and chronic lameness. The outcomes measured included measures of inflammation and outcomes related to physical discomfort.

Research for Equine Colic

Research examined outcomes related to physical discomfort associated with equine colic. Regulatory research highlights that study protocols require a professional re-evaluation if the observed pain relief is not adequate, which is a key part of the research context.

---

What is Still Uncertain About Animeloxan's Research

The evidence quality varies across studies, with reliance on bioequivalence findings to support the generic product in several indications. Comparative evidence is lacking regarding the product's independent contribution when study protocols require the use of concurrent therapy (such as antibiotics for mastitis or re-hydration for diarrhea). Long-term effects are not fully established beyond the short observation periods of the clinical trials.

Key Studies & References HPRA Veterinary Medicinal Product Overview / Summary of Product Characteristics (SPC) for Animeloxan

Common questions about Animeloxan (FAQ)

---

Q: What is Animeloxan used for, besides the main thing?

Official veterinary product information states that Animeloxan is also used as adjunctive therapy for certain conditions. This means it is used alongside other primary treatments, such as for acute respiratory infections and acute mastitis in cattle, or specific locomotor (movement) disorders and puerperal septicaemia in pigs.

---

Q: Are there any common foods or drinks that interact with Animeloxan?

Interactions with most common foods are generally not considered clinically significant. However, some authoritative sources advise caution or avoidance of grapefruit juice when using products containing Meloxicam. This is because compounds in grapefruit may potentially affect how the medicine is processed in the body, which could alter concentrations.

---

Q: What is the risk of having a serious interaction with Animeloxan?

Due to its classification, official documentation for Meloxicam products includes a serious safety warning (Boxed Warning) in human use labeling. This warning details the potential for serious health issues related to stomach and intestinal bleeding and certain cardiovascular risks. These risks may occur without clear warning. Official information identifies specific co-administered medicines and patient conditions that are restricted or prohibited.

---

Q: What if I accidentally take Animeloxan too close to bedtime?

Regulatory guidance suggests the medicine can generally be administered at any time of the day, as the time of administration is not considered critical for the medicine's action. Guidance suggests that taking the medicine consistently at the same time each day may help maintain the prescribed regimen.

---

Q: How does Animeloxan work in simple terms?

Animeloxan works by inhibiting (blocking) certain cyclooxygenase (COX) enzymes in the body. By reducing the activity of these enzymes, this action works to limit the production of prostaglandins. Prostaglandins are key chemical signals that cause pain, fever, and inflammation.

---

Q: How long does it usually take for Animeloxan to start working?

Clinical review documents indicate that the onset of action for Meloxicam is typically delayed. Due to this delay, the medicine is typically not used in clinical situations where very rapid relief from symptoms is the primary goal.

---

Q: What happens if I stop taking Animeloxan suddenly?

Official information indicates that any observed adverse reactions (side effects) are generally transient (temporary) and typically disappear following the termination of the treatment. The product labelling does not describe any specific physiological withdrawal syndrome upon stopping the medicine.

---

Q: Can older people use Animeloxan?

While specific studies have not demonstrated problems unique to the elderly, regulatory information notes that older patients are generally more likely to experience serious stomach, heart, or kidney issues while using NSAIDs. For this reason, specific caution is indicated, and a thorough assessment of individual risk factors is a necessary part of the prescribed use.

---

Q: Is it normal to feel a bit dizzy after starting Animeloxan?

Official product labeling lists dizziness as a potential adverse reaction. Official documentation identifies this as a common side effect, meaning it was reported with some frequency in clinical studies.

---

Q: Is Animeloxan associated with weight changes?

Official adverse reaction lists for Meloxicam include the potential for weight gain and edema (fluid retention or swelling) as potential side effects. These reactions are typically categorized under the full prescribing information.

---

Q: How long does Animeloxan stay in your system after you stop taking it?

Clinical pharmacology studies indicate that the active ingredient, Meloxicam, has an elimination half-life of approximately 20 hours. The half-life is the time it takes for half of the dose to be cleared from the system, which determines the overall clearance time.

---

Q: Why does the leaflet say to avoid grapefruit with Animeloxan?

Grapefruit is often noted to interact with various medicines because it can interfere with the way the body metabolizes (breaks down) certain drugs. If the medicine is not broken down as expected, the concentrations in the body could potentially increase, which is associated with a greater risk of side effects.

---

Q: Does Animeloxan affect birth control pills?

Regulatory information indicates that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like Meloxicam may interact with certain drospirenone-containing contraceptives. The potential for increased potassium concentration is noted, and this is a factor that is often monitored during use.

---

Q: Is it possible to become dependent on Animeloxan?

The active ingredient, Meloxicam, is not classified as a controlled substance by regulatory bodies. The official documentation indicates that its potential for physical dependence or abuse is generally considered low.

---

Q: Can Animeloxan make my skin more sensitive to the sun?

Yes, regulatory documents list photosensitivity as a potential adverse reaction associated with this medicine. Photosensitivity means the skin may experience an increased sensitivity or reaction to exposure to sunlight.

---

Q: Can Animeloxan interact with herbal remedies like St. John's Wort?

St. John's Wort is officially documented to interact with a wide range of medicines by influencing metabolic pathways. This may potentially reduce the plasma concentrations of various prescribed drugs, which could then decrease their expected therapeutic effects.

---

Q: Does the time of day I take Animeloxan matter?

While there is no mandatory time of day for administration, regulatory guidance suggests that taking the medicine consistently at the same time each day is considered a best practice. This approach is considered a best practice for maintaining consistency of the medicine's levels throughout the regimen.

---

Q: Is Animeloxan a new drug, or has it been around for a while?

The active ingredient, Meloxicam, has been used for several decades. The initial oral tablet formulation received its first major approval from the FDA in the year 2000.

How to Store and Dispose of Animeloxan

Animeloxan (Meloxicam Solution for Injection) must be stored and disposed of strictly according to regulatory guidelines to maintain stability and protect the environment.

---

Storage and Stability

The unopened product requires no special temperature storage conditions. The official shelf-life for the unopened vial is 3 years. However, once the container is first opened, the medicine is stable for only 28 days, and any remaining solution must be discarded after this period. The medicine must be kept out of the sight and reach of children.

---

Disposal Requirements

Unused or expired Animeloxan and waste materials must not be disposed of via wastewater or household trash. Disposal must be carried out in accordance with local regulatory requirements and guidelines provided by the local waste regulation authority.